168: Combined analysis of NT-proBNP and C-reactive protein improves their predictive value for development of cardiac allograft vasculopathy and all-cause mortality but not acute cellular rejection in heart transplant recipients

Methods and Materials: The Loyola HTx database was analyzed. A total of 65 pts had quantified HBV Tr. There were 2 groups (Gr): 1) positive HBV Tr ( 10mIU/mL), and 2) negative Tr ( 10mIU/mL). Data on VCN, HBV Tr, graft rejection (REJ), cardiac allograft vasculopathy (CAV), and severe infection (INF) were compared. Our HBV VCN protocol is injection of 20-40mcg of Recombivax® (Merck) at 0 (at HTx listing), 1, and 6 months (m). CAV by angiography was reported as negative (no lesions), mild (all lesions 50%), or severe ( 50% lesion in any major vessel). REJ was ISHLT grade 2 or a decrease in ejection fraction of 25% from previous echocardiography.